Walther A, Houlston R, Tomlinson I
Molecular and Population Genetics Laboratory, London Research Institute, Cancer Research UK, London, UK.
Gut. 2008 Jul;57(7):941-50. doi: 10.1136/gut.2007.135004. Epub 2008 Mar 25.
Several studies have suggested that microsatellite instability (MSI) resulting from defective DNA mismatch repair confers a better prognosis in colorectal cancer (CRC). Recently, however, data have suggested this is secondary to the effects of ploidy/chromosomal instability (CIN). To estimate the prognostic significance of CIN for survival, data from published studies have been reviewed and pooled.
Studies stratifying survival in CRC by CIN status were identified by searching PubMed and hand-searching bibliographies of identified studies. Two reviewers confirmed study eligibility and extracted data independently, and data were pooled using a fixed-effects model. The principal outcome measure was the HR for death.
63 eligible studies reported outcome in 10 126 patients, 60.0% of whom had CIN+ (aneuploid/polyploid) tumours. The overall HR associated with CIN was 1.45 (95% CI 1.35 to 1.55, p<0.001). In patients with stage II-III CRCs, the HR was 1.45 (95% CI 1.27 to 1.65, p<0.001). The effect was similar for progression-free survival (HR = 1.71, 95% CI 1.51 to 1.94, p<0.001). There was no evidence of significant interstudy heterogeneity.
CIN is associated with a worse prognosis in CRC, and should be evaluated as a prognostic marker, together with MSI status, in all clinical trials, particularly those involving adjuvant therapies.
多项研究表明,DNA错配修复缺陷导致的微卫星不稳定性(MSI)在结直肠癌(CRC)中预示着较好的预后。然而,最近的数据表明,这是倍性/染色体不稳定性(CIN)作用的结果。为评估CIN对生存的预后意义,对已发表研究的数据进行了回顾和汇总。
通过检索PubMed并手工检索已识别研究的参考文献,确定按CIN状态对CRC生存进行分层的研究。两名评审员确认研究的合格性并独立提取数据,使用固定效应模型汇总数据。主要结局指标是死亡风险比(HR)。
63项合格研究报告了10126例患者的结局,其中60.0%患有CIN+(非整倍体/多倍体)肿瘤。与CIN相关的总体HR为1.45(95%CI 1.35至1.55,p<0.001)。在II-III期CRC患者中,HR为1.45(95%CI 1.27至1.65,p<0.001)。无进展生存的效应相似(HR = 1.71,95%CI 1.51至1.94,p<0.001)。没有证据表明研究间存在显著异质性。
CIN与CRC预后较差相关,在所有临床试验中,尤其是那些涉及辅助治疗的试验中,应与MSI状态一起作为预后标志物进行评估。